Product: CEBPB Antibody
Catalog: BF0339
Description: Mouse monoclonal antibody to CEBPB
Application: WB ELISA FACS
Reactivity: Human
Mol.Wt.: 36kDa; 36kD(Calculated).
Uniprot: P17676
RRID: AB_2833944

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Mouse
Application:
ELISA 1:10000, WB 1:500-1:2000, FCM 1:200-1:400
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Monoclonal [AFB1921]
Specificity:
CEBPB antibody detects endogenous levels of total CEBPB.
RRID:
AB_2833944
Cite Format: Affinity Biosciences Cat# BF0339, RRID:AB_2833944.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AGP/EBP; C EBP beta; C/EBP beta; C/EBP related protein 2; CCAAT Enhancer Binding Protein beta; CCAAT/enhancer-binding protein beta; CEBPB; CEBPB_HUMAN; CRP2; IL 6DBP; IL6DBP; Interleukin 6 dependent binding protein; LAP; Liver activator protein; Liver enriched transcriptional activator; NF IL6; NFIL6; Nuclear factor NF IL6; Nuclear factor NF-IL6; SF B; SFB; Silencer factor B; TCF-5; TCF5; Transcription factor 5;

Immunogens

Immunogen:

Purified recombinant fragment of human CEBPB expressed in E. Coli.

Uniprot:
Gene(ID):
Expression:
P17676 CEBPB_HUMAN:

Expressed at low levels in the lung, kidney and spleen.

Description:
The protein encoded by this intronless gene is a bZIP transcription factor which can bind as a homodimer to certain DNA regulatory regions. It can also form heterodimers with the related proteins CEBP-alpha, CEBP-delta, and CEBP-gamma. The encoded protein is important in the regulation of genes involved in immune and inflammatory responses and has been shown to bind to the IL-1 response element in the IL-6 gene, as well as to regulatory regions of several acute-phase and cytokine genes. In addition, the encoded protein can bind the promoter and upstream element and stimulate the expression of the collagen type I gene.
Sequence:
MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC

PTMs - P17676 As Substrate

Site PTM Type Enzyme
R3 Methylation
S65 Phosphorylation
S76 Phosphorylation P06493 (CDK1)
Y78 Phosphorylation P42684 (ABL2) , P00519 (ABL1)
K129 Ubiquitination
K133 Sumoylation
Y137 Phosphorylation
Y139 Phosphorylation
S141 Phosphorylation
K149 Ubiquitination
K174 Sumoylation
K185 Ubiquitination
K187 Sumoylation
S218 Phosphorylation
S223 Phosphorylation P49841 (GSK3B)
T226 Phosphorylation P49841 (GSK3B)
S229 Phosphorylation
S230 Phosphorylation
S231 Phosphorylation P49841 (GSK3B)
T235 Phosphorylation Q9H2X6 (HIPK2) , Q15418 (RPS6KA1) , P27361 (MAPK3) , P28482 (MAPK1) , P24941 (CDK2)
Y249 Phosphorylation
S257 Phosphorylation
K260 Sumoylation
K260 Ubiquitination
K264 Acetylation
K265 Acetylation
T266 Phosphorylation
K269 Acetylation
K275 Sumoylation
K275 Ubiquitination
S288 Phosphorylation P17612 (PRKACA)
K302 Ubiquitination
K315 Ubiquitination
K316 Ubiquitination
S321 Phosphorylation Q15349 (RPS6KA2) , P51812 (RPS6KA3)
S325 Phosphorylation
K332 Sumoylation
K332 Ubiquitination

Research Backgrounds

Function:

Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing (By similarity). During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development (By similarity). Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation (By similarity).

Essential for gene expression induction in activated macrophages. Plays a major role in immune responses such as CD4(+) T-cell response, granuloma formation and endotoxin shock. Not essential for intracellular bacteria killing.

Acts as a dominant negative through heterodimerization with isoform 2. Promotes osteoblast differentiation and osteoclastogenesis (By similarity).

PTMs:

Methylated. Methylation at Arg-3 by CARM1 and at Lys-43 by EHMT2 inhibit transactivation activity. Methylation is probably inhibited by phosphorylation at Thr-235.

Sumoylated by polymeric chains of SUMO2 or SUMO3. Sumoylation at Lys-174 is required for inhibition of T-cells proliferation. In adipocytes, sumoylation at Lys-174 by PIAS1 leads to ubiquitination and subsequent proteasomal degradation. Desumoylated by SENP2, which abolishes ubiquitination and stabilizes protein levels (By similarity).

Ubiquitinated, leading to proteasomal degradation.

Phosphorylated at Thr-235 by MAPK and CDK2, serves to prime phosphorylation at Thr-226 and Ser-231 by GSK3B and acquire DNA-binding as well as transactivation activities, required to induce adipogenesis. MAPK and CDK2 act sequentially to maintain Thr-235 in the primed phosphorylated state during mitotical cloning expansion and thereby progression of terminal differentiation. Phosphorylation at Thr-266 enhances transactivation activity. Phosphorylation at Ser-325 in response to calcium increases transactivation activity. Phosphorylated at Thr-235 by RPS6KA1.

O-glycosylated, glycosylation at Ser-227 and Ser-228 prevents phosphorylation on Thr-235, Ser-231 and Thr-226 and DNA binding activity which delays the adipocyte differentiation program.

Acetylated. Acetylation at Lys-43 is an important and dynamic regulatory event that contributes to its ability to transactivate target genes, including those associated with adipogenesis and adipocyte function. Deacetylation by HDAC1 represses its transactivation activity. Acetylated by KAT2A and KAT2B within a cluster of lysine residues between amino acids 129-133, this acetylation is strongly induced by glucocorticoid treatment and enhances transactivation activity.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Translocates to the nucleus when phosphorylated at Ser-288. In T-cells when sumoylated drawn to pericentric heterochromatin thereby allowing proliferation (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed at low levels in the lung, kidney and spleen.

Subunit Structure:

Binds DNA as a homodimer and as a heterodimer. Interacts with ATF4. Binds DNA as a heterodimer with ATF4. Interacts with MYB; within the complex, MYB and CEBPB bind to different promoter regions. Can form stable heterodimers with CEBPD. Can form stable heterodimers with CEBPA and CEBPE (By similarity). Isoform 2 and isoform 3 also form heterodimers. Interacts with TRIM28 and PTGES2. Interacts with PRDM16. Interacts with CCDC85B. Forms a complex with THOC5. Interacts with ZNF638; this interaction increases transcriptional activation. Interacts with CIDEA and CIDEC; these interactions increase transcriptional activation of a subset of CEBPB downstream target genes (By similarity). Interacts with DDIT3/CHOP. Interacts with EP300; recruits EP300 to chromatin. Interacts with RORA; the interaction disrupts interaction with EP300. Interacts (not methylated) with MED23, MED26, SMARCA2, SMARCB1 and SMARCC1. Interacts with KAT2A and KAT2B (By similarity). Interacts with ATF5; EP300 is required for ATF5 and CEBPB interaction and DNA binding (By similarity). Interacts with NFE2L1; the heterodimer represses expression of DSPP during odontoblast differentiation (By similarity).

Family&Domains:

the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Belongs to the bZIP family. C/EBP subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

References

1). GRIM19 deficiency aggravates metabolic disorder and ovarian dysfunction in PCOS. Biochimica et biophysica acta. Molecular basis of disease, 2024 (PubMed: 38360073) [IF=6.2]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.